Compare Davita Inc (DVA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Charles Schwab Corporation Common Stock — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Charles Schwab Corporation Common Stock trades at $107.04 (market cap $186.75B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 15.9× Davita Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SCHW | |
|---|---|---|
Market Cap | $11.72B | $186.75B |
Sector | Health | Financials |
52-Week High | $240.96 | $108.02 |
52-Week Low | $103.87 | $85.35 |
Enterprise Value | $24.44B | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Charles Schwab (SCHW) trades at $107.60, down 0.06% on the day, near its all-time high of $109.05. The stock shows strong bullish momentum with earnings beats in recent quarters and a consensus analyst price target of $122.33. Revenue grew to $23.92 billion in 2025, with net income margin improving to 38.79%. Technical indicators signal bullish trends, though RSI levels suggest overbought conditions.
Outlook remains positive with robust earnings growth and institutional support, but risks include litigation exposure and competitive pressures. The stock offers upside potential aligned with analyst targets, contingent on sustained operational performance and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
